Cisplatin (Platinol ®)
Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
Thoracic Cancer 2021 April 8 [Link] Kageaki Watanabe, Yusuke Okuma, Shoko Kawai, Makoto Nagamata, Yukio Hosomi Abstract Background: Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next-generation anthracycline that is commonly used to…
Read MoreTreatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting
Future Oncology 2021 March 26 [Link] David M Waterhouse, Esmond D Nwokeji, Marley Boyd, John R Penrod, Janet L Espirito, Nicholas J Robert, Melinda J Daumont Abstract Aim: To assess real-world treatment patterns and outcomes among patients with advanced malignant pleural mesothelioma. Patients & methods: Retrospective database analysis. Results: In all, 469 patients received first-line…
Read MoreEfficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
BMC Cancer 2021 March 20 [Link] Rui Kitadai, Tatsunori Shimoi, Kazuki Sudo, Emi Noguchi, Yusuke Nagata, Ryoichi Sawada, Atsuo Takashima, Narikazu Boku, Kan Yonemori Abstract Background: Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is administered according to malignant pleural mesothelioma. We previously reported the efficacy of cisplatin plus pemetrexed…
Read MoreInvestigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed
European Journal of Pharmaceutical Sciences 2021 March 2 [Link] Aurélie Lombard, Hitesh Mistry, Sonya C Chapman, Ivelina Gueorguieva, Leon Aarons, Kayode Ogungbenro Abstract In the last update of the RECIST criteria in 2009, it was proposed that the number of target lesions to be followed over time for response-to-treatment assessment be reduced from 10 to…
Read MoreInvestigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed
European Journal of Pharmaceutical Sciences 2021 March 2 [Link] Aurélie Lombard, Hitesh Mistry, Sonya C Chapman, Ivelina Gueorguieva, Leon Aarons, Kayode Ogungbenro Abstract In the last update of the RECIST criteria in 2009, it was proposed that the number of target lesions to be followed over time for response-to-treatment assessment be reduced from 10 to…
Read MoreAlterations in BAP1 are Associated with Cisplatin Resistance Through Inhibition of Apoptosis in Malignant Pleural Mesothelioma (MPM)
Clinical Cancer Research 2021 February 5 [Link] Kathrin Oehl, Bart Vrugt, Ulrich Wagner, Michaela B Kirschner, Mayura Meerang, Walter Weder, Emanuela Felley-Bosco, Bernd Wollscheid, Katrin Bankov, Melanie C Demes, Isabelle Opitz, Peter J Wild Abstract Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of…
Read MoreFirst-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Lancet 2021 January 21 [Link] Paul Baas, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz Kowalski, Jerónimo Rodríguez-Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gérard Zalcman Abstract Background: Approved systemic treatments…
Read MoreEstablishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients
Cancers 2020 December 20 [Link] Roberta Affatato, Paolo Mendogni, Alessandro Del Gobbo, Stefano Ferrero, Francesca Ricci, Massimo Broggini, Lorenzo Rosso Abstract Background: Malignant pleural mesothelioma (MPM) is a very aggressive tumor originating from mesothelial cells. Although several etiological factors were reported to contribute to MPM onset, environmental exposure to asbestos is certainly a major risk…
Read MoreThe Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis
Frontiers in Oncology 2020 November 13 [Link] Olivia Lauk, Karina Bruestle, Thomas Neuer, Bianca Battilana, Thi Dan Linh Nguyen, Thomas Frauenfelder, Rolf Stahel, Walter Weder, Alessandra Curioni-Fontecedro, Isabelle Opitz Abstract Objectives: Adding bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF), to platinum-based chemotherapy/pemetrexed in 1st line treatment of advanced malignant pleural mesothelioma (MPM), significantly improved overall…
Read MoreOncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716
Lung Cancer 2020 October 20 [Link] Sarah J Danson, Joe Conner, John G Edwards, Kevin G Blyth, Patricia M Fisher, Munitta Muthana, Abdulazeez Salawu, Fiona Taylor, Elizabeth Hodgkinson, Patrick Joyce, Jennifer Roman, Kathleen Simpson, Alexander Graham, Kirsty Learmonth, Penella J Woll Abstract Objectives: Malignant Pleural Mesothelioma (MPM) remains a major oncological challenge with limited therapeutic…
Read More